Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-06-27

FDA Approved: KIMMTRAK — Supplemental Application (Immunocore Commercial LLC)

View source ↗

Summary

FDA approved a supplemental Biologics License Application for KIMMTRAK (tebentafusp) from Immunocore Commercial LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KIMMTRAK (tebentafusp)

Snippet

SUPPL AP for KIMMTRAK (TEBENTAFUSP)